Korean J Pathol.
1999 Jul;33(7):475-482.
Correlation between Clinical Outcome and Proliferation Index in Diffuse Large B-Cell Lymphoma
- Affiliations
-
- 1Department of Pathology, Seoul National University College of Medicine, Seoul 110-799, Korea.
- 2Department of Internal Medicine, Seoul National University College of Medicine, Seoul 110-799, Korea.
- 3Department of Pathology, Ulsan University College of Medicine.
- 4Department of Pathology, Korea Cancer Center Hospital.
- 5Department of Internal Medicine, Korea Cancer Center Hospital.
Abstract
- The diffuse large B-cell lymphoma category of the Revised European American
Classification of Lymphoid Neoplasms (REAL) encompasses different morphologic
lymphoma subtypes in a single entity, especially the diffuse large cell (DLC) and the
immunoblastic (IBL) subtypes by Working Formulation (WF). The aim of this study is
to determine the influence of the morphologic subdivision within this category with
respect to clinical outcome and proliferative index using Ki-67 immunostainig combined
with image analysis. We retrospectively reviewed 74 patients from 1990 to 1996, who
were diagnosed with diffuse large B-cell lymphoma. All cases were reclassified according
to REAL and Working Formulation (WF), and Ki-67 immunostaining was performed in
all the cases. Fifty-eight cases (78.4%) were classified as DLC and 16 cases (21.6%) as
IBL, according to WF. Twenty one cases (28.4%) showed nodal involvement and 53
cases (71.6%), extranodal involvement. All cases were found to display a variable degree
of nuclear Ki-67 staining. A proliferative index of 50% or higher identified a group of
patients (77%) who had poor clinical results. Overall survival was significantly reduced
in these patients displaying high Ki-67 associated proliferative index compared to those
with a low proliferative index (p=0.007). 5-year survival estimates were 93% in the low
proliferative index group and 55% in the high proliferative index group. A multivariate
regression analysis incorporating commonly used clinical prognostic factors confirmed the
independent effect of proliferation index on survival. Moreover, all of the 16 IBL cases
showed Ki-67 positivity of 50% or higher, which correlates with the poor clinical
outcome compared to 70.7% of DLC (p=0.014). We conclude that subdivision of the
diffuse large B-cell lymphoma category of the REAL classification is necessary in terms
of prognostic significance in correlation with Ki-67 proliferative index.